ArticleThe Journal of clinical investigation2011
NKp46 identifies an NKT cell subset susceptible to leukemic transformation in mouse and human.
Article in The Journal of clinical investigation, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 67 citations in OpenAlex.
- Advancements in the Study of the Immune Molecule NKp46 in Immune System-related Diseases.Clinical reviews in allergy & immunology · 2024Review
- Thymic NK-Cells and Their Potential in Cancer Immunotherapy.ImmunoTargets and therapy · 2024Review
- Cationic Polyethyleneimine (PEI)-Gold Nanocomposites Modulate Macrophage Activation and Reprogram Mouse Breast Triple-Negative MET-1 Tumor Immunological Microenvironment.Pharmaceutics · 2022Article
- Harnessing IL-15 signaling to potentiate NK cell-mediated cancer immunotherapy.Trends in immunology · 2022Review
- Cellular Origins and Pathogenesis of Gastrointestinal NK- and T-Cell Lymphoproliferative Disorders.Cancers · 2022Review
- Adipocyte CD1d Gene Transfer Induces T Cell Expansion and Adipocyte Inflammation in CD1d Knockout Mice.Journal of immunology (Baltimore, Md. : 1950) · 2022Article
- PDGF-D-PDGFRβ signaling enhances IL-15-mediated human natural killer cell survival.Proceedings of the National Academy of Sciences of the United States of America · 2022Article
- Parity-induced changes to mammary epithelial cells control NKT cell expansion and mammary oncogenesis.Cell reports · 2021Article
- Single-cell profiling reveals the trajectories of natural killer cell differentiation in bone marrow and a stress signature induced by acute myeloid leukemia.Cellular & molecular immunology · 2021Article
- High-Dimensional Flow Cytometry Analysis of Regulatory Receptors on Human T Cells, NK Cells, and NKT Cells.Methods in molecular biology (Clifton, N.J.) · 2021Article
- Single injection of IL-12 coacervate as an effective therapy against B16-F10 melanoma in mice.Journal of controlled release : official journal of the Controlled Release Society · 2020Article
- STAT5BLeukemia · 2019Article
- Adipocytes: A Novel Target for IL-15/IL-15Rα Cancer Gene Therapy.Molecular therapy : the journal of the American Society of Gene Therapy · 2019Article
- Styk1 expression is a hallmark of murine NK cells and other NK1.1European journal of immunology · 2019Article
- The Natural Cytotoxicity Receptors in Health and Disease.Frontiers in immunology · 2019Review
- Mutated Von Hippel-Lindau-renal cell carcinoma (RCC) promotes patients specific natural killer (NK) cytotoxicity.Journal of experimental & clinical cancer research : CR · 2018Article
- Distinct human circulating NKp30Proceedings of the National Academy of Sciences of the United States of America · 2018Article
- Dependence of innate lymphoid cell 1 development on NKp46.PLoS biology · 2018Article
- Role of NKp46EMBO molecular medicine · 2018Article
- Complement factor P is a ligand for the natural killer cell-activating receptor NKp46.Science immunology · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 3 institutions in 2 countries.
Funding
Abstract
IL-15 may have a role in the development of T cell large granular lymphocyte (T-LGL) or NKT leukemias. However, the mechanisms of action and the identity of the cell subset that undergoes leukemic transformation remain elusive. Here we show that in both mice and humans, NKp46 expression marks a minute population of WT NKT cells with higher activity and potency to become leukemic. Virtually 100% of T-LGL leukemias in IL-15 transgenic mice expressed NKp46, as did a majority of human T-LGL leukemias. The minute NKp46+ NKT population, but not the NKp46⁻ NKT population, was selectively expanded by overexpression of endogenous IL-15. Importantly, IL-15 transgenic NKp46⁻ NKT cells did not become NKp46+ in vivo, suggesting that NKp46+ T-LGL leukemia cells were the malignant counterpart of the minute WT NKp46+ NKT population. Mechanistically, NKp46+ NKT cells possessed higher responsiveness to IL-15 in vitro and in vivo compared with that of their NKp46⁻ NKT counterparts. Furthermore, interruption of IL-15 signaling using a neutralizing antibody could prevent LGL leukemia in IL-15 transgenic mice. Collectively, our data demonstrate that NKp46 identifies a functionally distinct NKT subset in mice and humans that appears to be directly susceptible to leukemic transformation when IL-15 is overexpressed. Thus, IL-15 signaling and NKp46 may be useful targets in the treatment of patients with T-LGL or NKT leukemia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.